Disease · MONDO_0005059
Comparisons in its trials37
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 37
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
Arm 1: Participants w/Hematologic Malignancies Treated w/Fludarabine/TS Busulfan AUC 16,000 Umol/l vs Arm 2: Participants w/Hematologic Malignancies Treated w/Fludarabine/TS Busulfan AUC 20,000umol/l.: Overall Survival | 16 of 49 | 47 of 150 | 199 | NCT01572662 | Trial comparisons |
Arm 1: Participants w/Hematologic Malignancies Treated w/Fludarabine/TS Busulfan AUC 16,000 Umol/l vs Arm 2: Participants w/Hematologic Malignancies Treated w/Fludarabine/TS Busulfan AUC 20,000umol/l.: Non-Relapse Mortality Rate (NRM) | 2 of 49 | 8 of 150 | 199 | NCT01572662 | Trial comparisons |
Arm 1: Participants w/Hematologic Malignancies Treated w/Fludarabine/TS Busulfan AUC 16,000 Umol/l vs Arm 2: Participants w/Hematologic Malignancies Treated w/Fludarabine/TS Busulfan AUC 20,000umol/l.: Overall Survival | 29 of 49 | 93 of 150 | 199 | NCT01572662 | Trial comparisons |
Arm 1: Participants w/Hematologic Malignancies Treated w/Fludarabine/TS Busulfan AUC 16,000 Umol/l vs Arm 2: Participants w/Hematologic Malignancies Treated w/Fludarabine/TS Busulfan AUC 20,000umol/l.: deaths from any cause | 31 of 49 | 93 of 150 | 199 | NCT01572662 | Trial comparisons |
Arm 1: Participants w/Hematologic Malignancies Treated w/Fludarabine/TS Busulfan AUC 16,000 Umol/l vs Arm 2: Participants w/Hematologic Malignancies Treated w/Fludarabine/TS Busulfan AUC 20,000umol/l.: serious adverse events | 6 of 49 | 8 of 150 | 199 | NCT01572662 | Trial comparisons |
| Cohort A (GSK1120212 < 24 Weeks) vs Cohort B (GSK1120212 >= 24 Weeks): deaths from any cause | 13 of 126 | 3 of 33 | 159 | NCT01376310 | Trial comparisons |
| Cohort A (GSK1120212 < 24 Weeks) vs Cohort B (GSK1120212 >= 24 Weeks): serious adverse events | 26 of 126 | 13 of 33 | 159 | NCT01376310 | Trial comparisons |
| G-CSF (Granulocyte Colony- Stimulating Factor) vs G-CSF and GM-CSF (Granulocyte Macrophage): serious adverse events | 7 of 25 | 7 of 25 | 50 | NCT00208949 | Trial comparisons |
| Arm I: Glutamine vs Arm II: Placebo: Incidence of Vincristine-induced Peripheral Neuropathy | 24 of 24 | 25 of 25 | 49 | NCT00365768 | Trial comparisons |
| Arm I: Glutamine vs Arm II: Placebo: Number of Participants With Progression of Neuropathy | 11 of 24 | 19 of 25 | 49 | NCT00365768 | Trial comparisons |
| Arm I: Glutamine vs Arm II: serious adverse events | 0 of 24 | 0 of 25 | 49 | NCT00365768 | Trial comparisons |
| Treatment (Vosaroxin, Cytarabine) Induction 1 vs Induction 2: deaths from any cause | 18 of 33 | 4 of 9 | 42 | NCT02658487 | Trial comparisons |
| Treatment (Vosaroxin, Cytarabine) Induction 1 vs Induction 2: serious adverse events | 10 of 33 | 5 of 9 | 42 | NCT02658487 | Trial comparisons |
| Arm A (Veliparib, Topotecan Hydrochloride, Carboplatin) vs Arm B (Topotecan Hydrochloride, Carboplatin): Number of Participants Still Alive at Study Completion | 5 of 16 | 5 of 9 | 25 | NCT03289910 | Trial comparisons |
| Arm A (Veliparib, Topotecan Hydrochloride, Carboplatin) vs Arm B (Topotecan Hydrochloride, Carboplatin): deaths from any cause | 11 of 16 | 4 of 9 | 25 | NCT03289910 | Trial comparisons |
| Arm A (Veliparib, Topotecan Hydrochloride, Carboplatin) vs Arm B (Topotecan Hydrochloride, Carboplatin): Number of Participants Without Disease at Study Completion | 3 of 16 | 3 of 9 | 25 | NCT03289910 | Trial comparisons |
| Arm A (Veliparib, Topotecan Hydrochloride, Carboplatin) vs Arm B (Topotecan Hydrochloride, Carboplatin): serious adverse events | 4 of 16 | 4 of 9 | 25 | NCT03289910 | Trial comparisons |
| Chronic Lymphocytic Leukemia vs Acute Lymphocytic Leukemia: serious adverse events | 14 of 14 | 6 of 6 | 20 | NCT01029366 | Trial comparisons |
| 40 mg/m2 Dose vs 52 mg/m2 Dose: deaths from any cause | 1 of 6 | 5 of 12 | 18 | NCT01041508 | Trial comparisons |
| 40 mg/m2 Dose vs 52 mg/m2 Dose: serious adverse events | 1 of 6 | 0 of 12 | 18 | NCT01041508 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005059/comparisons